Tesaro Announces Participation In Three Investor Conferences

WALTHAM, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor conferences. The three conferences are:
  • The Leerink POLARxPRESS Bus Tour at the Convene Conference Center in New York, New York on Wednesday, November 30. Tim Pearson, EVP and CFO of TESARO, will present on November 30 at 9:45 AM ET. 
  • The Citi 2016 Global Healthcare Conference at the Lotte New York Palace in New York, New York on Wednesday, December 7. Lonnie Moulder, CEO of TESARO, Mary Lynne Hedley, Ph.D., President and COO of TESARO, and Tim Pearson, EVP and CFO of TESARO, will participate in an analyst-led moderated Q&A from 3:40 to 4:20 PM ET and in meetings with investors. 
  • The Guggenheim Securities 4 th Annual Boston Healthcare Conference at the Intercontinental in Boston, Massachusetts on Tuesday, December 13. Tim Pearson, EVP and CFO of TESARO, will participate in meetings with investors.

A live webcast of the presentation at the Citi conference will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. An archived replay of this webcast will be available on the Company's website for 14 days following the conference.

About TESAROTESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact:     Jennifer Davis1.781.325.1116jdavis@tesarobio.com

Primary Logo

If you liked this article you might like

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks to Watch in 2018

10 Biotech Stocks to Watch in 2018

DBV Rises On Phase 3 Results for Peanut Allergy Treatment -- Biotech Movers

DBV Rises On Phase 3 Results for Peanut Allergy Treatment -- Biotech Movers

Ophthotech Soars After Third-Quarter Results -- Biotech Movers

Ophthotech Soars After Third-Quarter Results -- Biotech Movers